Update Note: This article reports new information involving the experimental weight-loss drug petrelintide following MedicalDaily's earlier coverage. The newest data come from the peer-reviewed trial paper published September 29, 2026, in The Lancet Diabetes & Endocrinology and presented at the EASD annual meeting in Milan on September 30, 2026.
Full, peer-reviewed results for petrelintide, an experimental once-weekly amylin injection, show that adults with excess weight lost between 8.7% and 10.7% of their body weight over 42 weeks, compared with 1.7% on placebo. Nausea was reported by 20% of people on the drug vs. 6% on placebo. The findings were published in The Lancet Diabetes & Endocrinology.
